In all the aforementioned studies, increased sCD163 evaluated with ELISA and CD163+ TAMs tumor infiltration evaluated with immunohistochemistry were indicative of unfavorable prognosis, poorer outcome, rapid progression, and increased likelihood of treatment resistance or recurrence. The gene discussed is CD163; the disease is neoplasm.